These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 27151373)
21. Ondansetron Use in Pregnancy and Birth Defects: A Systematic Review. Carstairs SD Obstet Gynecol; 2016 May; 127(5):878-883. PubMed ID: 27054939 [TBL] [Abstract][Full Text] [Related]
22. Major Congenital Malformation Risk After First Trimester Gestational Exposure to Oral or Intravenous Ondansetron. Andrade C J Clin Psychiatry; 2020 Jun; 81(3):. PubMed ID: 32526103 [TBL] [Abstract][Full Text] [Related]
23. Metoclopramide and diphenhydramine in the treatment of hyperemesis gravidarum: effectiveness and predictors of rehospitalisation. Lacasse A; Lagoutte A; Ferreira E; Bérard A Eur J Obstet Gynecol Reprod Biol; 2009 Mar; 143(1):43-9. PubMed ID: 19135291 [TBL] [Abstract][Full Text] [Related]
24. Ondansetrone or metoclopromide? Which is more effective in severe nausea and vomiting of pregnancy? A randomized trial double-blind study. Kashifard M; Basirat Z; Kashifard M; Golsorkhtabar-Amiri M; Moghaddamnia A Clin Exp Obstet Gynecol; 2013; 40(1):127-30. PubMed ID: 23724526 [TBL] [Abstract][Full Text] [Related]
25. Gaining Insight Into Ondansetron Safety in Early Pregnancy. Lavecchia M; Chari R; Ross S J Obstet Gynaecol Can; 2019 Apr; 41(4):419-420. PubMed ID: 30685231 [No Abstract] [Full Text] [Related]
26. Assessment of discharge treatment prescribed to women admitted to hospital for hyperemesis gravidarum. Fiaschi L; Housley G; Nelson-Piercy C; Gibson J; Raji A; Deb S; Tata LJ Int J Clin Pract; 2019 Jan; 73(1):e13261. PubMed ID: 30239072 [TBL] [Abstract][Full Text] [Related]
27. Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis. Kaplan YC; Richardson JL; Keskin-Arslan E; Erol-Coskun H; Kennedy D Reprod Toxicol; 2019 Jun; 86():1-13. PubMed ID: 30849498 [TBL] [Abstract][Full Text] [Related]
29. Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum. Koren G; Maltepe C J Obstet Gynaecol; 2004 Aug; 24(5):530-3. PubMed ID: 15369934 [TBL] [Abstract][Full Text] [Related]
30. Antiemetic use among pregnant women in the United States: the escalating use of ondansetron. Taylor LG; Bird ST; Sahin L; Tassinari MS; Greene P; Reichman ME; Andrade SE; Haffenreffer K; Toh S Pharmacoepidemiol Drug Saf; 2017 May; 26(5):592-596. PubMed ID: 28220993 [TBL] [Abstract][Full Text] [Related]
31. Publishing negative findings and the challenge of avoiding type II errors in studies of suspect teratogens: Example of a recent ondansetron publication. Edlavitch SA Reprod Toxicol; 2017 Jan; 67():125-128. PubMed ID: 27988282 [TBL] [Abstract][Full Text] [Related]
39. Safety considerations surrounding use of treatment options for nausea and vomiting in pregnancy. Koren G Expert Opin Drug Saf; 2017 Nov; 16(11):1227-1234. PubMed ID: 28749713 [TBL] [Abstract][Full Text] [Related]
40. Pregnant women report being denied medications to treat severe nausea and vomiting of pregnancy or hyperemesis gravidarum - findings from an Australian online survey. Hsiao HF; Thomas A; Kay-Smith C; Grzeskowiak LE Aust N Z J Obstet Gynaecol; 2021 Aug; 61(4):616-620. PubMed ID: 33984156 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]